POLB Poolbeg Pharma Plc

TIDMPOLB

Poolbeg Pharma PLC

13 September 2021

RNS Reach

Poolbeg Pharma plc

Poolbeg Pharma to present at investor conferences

13 September 2021 - Poolbeg Pharma (AIM: POLB), 'Poolbeg' or the 'Company', a clinical stage infectious disease pharmaceutical company with a capital light clinical model, today announces that members of its management team will be attending four upcoming investor events across September and October.

   --      Proactive Investors One2One Forum (virtual) on 16 Sep 2021. Registration Link: click here 

-- Small Company Champion Investor Presentation on 17 Sep 2021 at The Menphys Hub, Bassett Street South, Wigston, Leicester LE18 4PE. Registration Link: click here

-- Shares Magazine Investor Webinar (virtual) on 5 Oct 2021. Registration link will be available on the Poolbeg Pharma website: click here

-- London South East Webinar (virtual) on 19 Oct 2021. Registration link will be available on the Poolbeg Pharma website: click here

The above event details may be subject to change. Further information and any updates will be on the events section of the Poolbeg Pharma website.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma , said:

"Following continuing demand after an oversubscribed AIM listing in July and a share price above the IPO price, I am looking forward to sharing how our capital light model and a scalable platform for growth will deliver value creation for our shareholders. Poolbeg Pharma is targeting a rapidly expanding market of infectious diseases, which is expected to exceed $250B by 2025. These events will be an opportunity to discuss our attractive, Phase II ready lead asset (POLB 001) tackling the inflammatory response to severe influenza, and our special access to a unique data bank of 20 years of infectious disease data in humans which we will mine to identify new, compelling therapeutics."

- Ends -

Enquiries

 
  Poolbeg Pharma Plc 
   Jeremy Skillington, CEO 
   Ian O'Connell, CFO                         +353 (0) 1 644 0007 
  finnCap Ltd (Nominated Adviser & Joint 
   Broker) 
   Geoff Nash, James Thompson, Charlie 
   Beeson                                     +44 (0) 20 7220 0500 
  Arden Partners PLC (Joint Broker) 
   John Lewellyn-Lloyd, Louisa Waddell, 
   Oscair McGrath                             +44 (0) 207 614 5900 
  J&E Davy (Joint Broker) 
   Anthony Farrell, Niall Gilchrist           +353 (0) 1 679 6363 
  Instinctif Partners                         +44 (0) 20 7457 2020 
   Melanie Toyne Sewell, Rozi Morris, Tim      poolbeg@instinctif.com 
   Field 
 

About Poolbeg Pharma

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a "one-stop shop" for Big Pharma seeking mid-stage products to licence or acquire.

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.

With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. It already has a Phase II ready repositioned small molecule immunomodulator for severe influenza and a portfolio of other exciting assets. The Company plans to broaden this portfolio further going forward and is in active discussions with AI data analysis platforms to help accelerate the power of its human challenge model data and biobank.

For more information, please go to www.poolbegpharma.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRALMMRTMTMBBTB

(END) Dow Jones Newswires

September 13, 2021 02:00 ET (06:00 GMT)

Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024